The event-free survival benefit with perioperative pembrolizumab in early NSCLC depends on the post-neoadjuvant residual tumor, suggested analysis.
SAN DIEGO — The degree of event-free survival after surgery in early-stage non–small cell lung cancer depends on the amount of residual tumor, according to a post hoc analysis of the KEYNOTE-671 study.
An exploratory analysis suggested there was an EFS benefit with pembrolizumab vs placebo in patients who experienced a pathologic complete or major pathologic response, but there was a need to study the relationship in a more granular manner. Jones explained that both the groups were"well matched, specifically for sex, tumor histology, tumor stage, and tumor PD-L1 status."
Among those with a %RVT of 0% to ≤ 5%, 24-month EFS was 90.8%, which fell to 74.7% in those with a %RVT > 5% to ≤ 30%, 62.1% in patients with a %RVT > 30% to ≤ 60%, and 40.2% among those with a %RVT > 60%. She noted that 3-year EFS/disease-free rates with neoadjuvant, perioperative, and adjuvant immunotherapy/chemotherapy approaches in stage II-III NSCLC are approximately 53%-65%.
Nsclc Lung Cancer Lung Carcinoma Cancer Of The Lung Neoadjuvant Tumor Perioperative Biologic Therapy Biologics Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Small Cell Lung Cancer Small-Cell Lung Cancer Oat Cell Lung Cancer SCLC Surgery Chemotherapy Immunotherapy Lung
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Immunotherapy and Survival in Advanced NSCLC: Does Obesity Matter?An obesity paradox does exist, but among patients with overweight or obesity, frontline immunotherapy was not associated with a survival benefit compared with chemotherapy, new data suggested.
Read more »
FDA Approves Neoadjuvant/Adjuvant Durvalumab for NSCLCThis approval follows recent concerns from an FDA committee that AstraZeneca did not demonstrate that patients needed the immunotherapy both before and after surgery.
Read more »
Ivonescimab: Possible New First-Line Standard in PD-L1-Positive Advanced NSCLC?The investigational PD-1/VEGF bi-specific immunotherapy agent showed a clinically significant progression-free survival over pembrolizumab in advanced PD-L1-positive NSCLC.
Read more »
Exploratory Data Support Both Adjuvant and Neoadjuvant Nivolumab for NSCLCInvestigators analyzed patient-level data from the phase 3 CheckMate 77T and 816 trials.
Read more »
Osimertinib/Savolitinib Combo Shows Promise in NSCLCOsimertinib plus savolitinib demonstrated stronger efficacy than osimertinib alone in patients with de novo MET-aberrant, EGFR-mutant advanced NSCLC in the FLOWERS study.
Read more »
Does Pleural Invasion Lead to Worse Outcomes in Early NSCLC?Individuals with small, peripheral, node-negative NSCLC and visceral pleural invasion had higher recurrence rates than those without pleural involvement, but similar overall survival rates.
Read more »